GlassScriptPhysician profile
Alden Bunyan
NPI 1265175574
$8,677.04
in general payments reported to CMS, 2019-2025
36 companies · $3,578 in 2025
The $3,578 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,104 · 2024: $2,994 · 2025: $3,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,536 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,536.31 |
| Education | $140.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,751.68 | 2023-2025 | |
| Amgen INC. | $1,557.62 | 2023-2025 | Evenity, Enbrel, Otezla |
| Ucb, INC. | $682.27 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $632.70 | 2023-2025 | Taltz, Zepbound |
| Janssen Biotech, INC. | $569.96 | 2023-2025 | Tremfya |
| Radius Health, INC. | $441.89 | 2023-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $417.96 | 2023-2025 | |
| Pfizer INC. | $333.28 | 2024-2025 | |
| Glaxosmithkline, LLC. | $289.08 | 2023-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $248.37 | 2023-2025 | Saphnelo |
| Alexion Pharmaceuticals, INC. | $180.28 | 2023-2025 | Strensiq, Ultomiris |
| Ani Pharmaceuticals, INC. | $161.95 | 2023-2025 | Purified Cortrophin Gel |
| Argenx US, INC. | $142.16 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Sobi, INC | $120.76 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $107.87 | 2023-2025 | Lupkynis |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $105.13 | 2024 | Arcalyst |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.24 | 2024 | Xifaxan |
| Mallinckrodt Hospital Products INC. | $83.25 | 2024-2025 | Acthar |
| Octapharma USA, INC. | $78.52 | 2024-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.51 | 2023-2024 | Cyltezo |
| Depuy Synthes Sales INC. | $71.85 | 2023-2025 | Monovisc, Orthovisc |
| Kiniksa Pharmaceuticals, LTD. | $66.79 | 2023 | Arcalyst |
| Alvogen INC | $62.96 | 2023-2024 | Teriparatide |
| Fidia Pharma USA INC. | $61.04 | 2023 | Hymovis, Triluron |
| Genentech USA, INC. | $59.96 | 2024 | Actemra |
| Horizon Therapeutics Plc | $49.67 | 2023 | Krystexxa |
| Avanos Medical | $41.30 | 2024 | Trivisc Sodium Hyaluronate |
| Organon LLC | $31.71 | 2023 | Hadlima |
| Zimmer Biomet Holdings, INC. | $29.56 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Alnylam Pharmaceuticals INC. | $22.48 | 2023 | Amvuttra |
| Catalyst Pharmaceuticals, INC. | $21.53 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.94 | 2024 | Hyqvia |
| Eisai INC. | $18.93 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $17.82 | 2024 | Zilretta |
| Ferring Pharmaceuticals INC. | $17.03 | 2025 | Euflexxa |
| Celltrion USA INC. | $14.99 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alden Bunyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.